The first therapeutic cancer vaccine of prostate cancer approved by FDA is Sipuleucel-T, which is essentially an autologous ex-vivo dendritic cell-based vaccine, pulsed with a single antigen of prostatic acid phosphatase (PAP) fused to GM-CSF [3, 4]. The gene discussed is CSF2; the disease is prostate cancer.